Fig. 2From: A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patientsPatient disposition. *Includes discontinuations due to serious adverse events, adverse events, or adverse drug reactions (some patients discontinued because of multiple events). †These patients were included in the safety analysis. BPI Brief Pain Inventory; FAS full analysis setBack to article page